A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

This study is for adults aged 18 or over who have advanced or recurring solid cancers. This means their cancer has either spread, returned, or hasn't responded to other available treatments. To join, your cancer must be a 'solid tumor' (not a blood cancer) and doctors need to be able to measure it using scans.

There are also some important health requirements. You need to be generally well enough to take part, meaning you can mostly look after yourself and do light activities. Organ functions like your liver need to be working properly. You'll also need to have a recent tissue sample (biopsy) taken to help doctors understand your cancer better.

However, some conditions would mean you can't join. For example, if you have certain active autoimmune diseases, a history of serious bleeding problems, or specific heart conditions. Also, if you have an active infection needing treatment, or have certain liver or bowel conditions, you wouldn't be able to participate. Women must not be pregnant or breastfeeding and, if they could become pregnant, must use effective contraception.

If you join this study, you will receive the new medicine GSK3745417, either by itself or along with dostarlimab. Both medicines are given through a drip (intravenous infusion). The study starts with a 'dose escalation' phase, which means participants will receive gradually increasing doses of the medicine to find the safest and most effective amount. You will have regular visits to the hospital for checks, which will include blood tests, urine tests, physical exams, and scans (like CT scans) to see how the cancer is responding. You will also be asked to provide a fresh tissue sample (biopsy) before starting treatment. The total duration of your participation will depend on how you respond to the treatment and the study plan, but it will involve regular hospital visits and follow-up for a period of time.